Status: Not yet recruiting
Role of Omega-DEK in Childhood Apraxia of Speech
This is a 20-week study for children between 3 and 6 years old with confirmed childhood apraxia of speech (CAS). The study includes a 12-week open-label pilot feasibility study of an investigational drug (Omega-DEK) plus L-carnitine (Carnitor®), which is followed by an 8-week randomized, placebo-controlled discontinuation period among the same study participants.
Participants needed: 34
Trial details
Phase: Phase 2Age: 2-6Biological sex: AllType: InterventionalSponsor: Claudia R. MorrisUpdated: Feb 27, 2026Locations: 2
Eligibility criteria
Confirmed diagnosis of childhood apraxia of speech/verbal apraxia by a qualified... [+2]
Children unable to tolerate oral supplementation [+22]